Contrasting DexCom (NASDAQ:DXCM) & Butterfly Network (NYSE:BFLY)

Butterfly Network (NYSE:BFLY – Get Free Report) and DexCom (NASDAQ:DXCM – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, risk, earnings, analyst recommendations and profitability.

Institutional and Insider Ownership

37.8% of Butterfly Network shares are owned by institutional investors. Comparatively, 97.8% of DexCom shares are owned by institutional investors. 22.0% of Butterfly Network shares are owned by insiders. Comparatively, 0.3% of DexCom shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Butterfly Network and DexCom”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Butterfly Network $123.25 million 11.70 -$77.06 million ($0.21) -25.67
DexCom $4.66 billion 6.35 $836.30 million $2.55 31.11

DexCom has higher revenue and earnings than Butterfly Network. Butterfly Network is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Butterfly Network has a beta of 2.16, suggesting that its stock price is 116% more volatile than the S&P 500. Comparatively, DexCom has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500.

Profitability

This table compares Butterfly Network and DexCom’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Butterfly Network -43.56% -21.60% -14.25%
DexCom 19.42% 37.77% 15.98%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Butterfly Network and DexCom, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Butterfly Network 1 1 5 1 2.75
DexCom 0 2 24 2 3.00

Butterfly Network currently has a consensus price target of $8.75, suggesting a potential upside of 62.34%. DexCom has a consensus price target of $95.50, suggesting a potential upside of 20.40%. Given Butterfly Network’s higher probable upside, research analysts clearly believe Butterfly Network is more favorable than DexCom.

Summary

DexCom beats Butterfly Network on 11 of the 15 factors compared between the two stocks.

About Butterfly Network

(Get Free Report)

Butterfly Network develops portable ultrasound technology for healthcare professionals. Its handheld devices use the company’s semiconductor-based Ultrasound-on-Chip technology to produce ultrasound images and connect with compatible mobile devices, offering an alternative to larger, cart-based systems. The company’s products include the Butterfly iQ line of handheld ultrasound devices, along with software and cloud-based tools for viewing, managing and sharing medical images. Its offerings are designed for use across a range of clinical settings and applications.

About DexCom

(Get Free Report)

DexCom, Inc. develops and markets continuous glucose monitoring (CGM) systems for people with diabetes. Its wearable sensors measure glucose levels throughout the day and send readings to compatible receivers or mobile devices, helping users monitor glucose trends and support treatment decisions. The company’s products include its Dexcom G6 and G7 CGM systems, along with software and connected services for users and caregivers. DexCom also offers Stelo, an over-the-counter glucose biosensor designed for adults who do not use insulin.

Receive News & Ratings for Butterfly Network Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Butterfly Network and related companies with MarketBeat.com's FREE daily email newsletter.